Rheumatic disease patients average 7-12 concurrent medications. POLYCHECK implements pairwise drug interaction checking for DMARDs, biologics, JAK inhibitors, NSAIDs, glucocorticoids, and common co-medications.
Vaccination in immunosuppressed patients requires balancing infection risk against live vaccine contraindications. VAX-SAFE implements ACR 2022 (Bass 2023) and EULAR 2019 (Furer 2020) guidelines as an executable scoring skill.
Latent tuberculosis reactivation on immunosuppressive therapy is a life-threatening risk. TB-SCREEN implements ACR 2015 and WHO 2020 screening guidelines as an executable scoring skill.
Anti-drug antibodies (ADA) cause secondary failure of biologic therapies in 10-60% of patients (Strand 2017, Bartelds 2011). ADA-Predictor is an executable skill that quantifies immunogenicity risk across 10 weighted domains: biologic type, concomitant methotrexate, HLA-DQA1*05 carrier status, prior biologic failure, disease activity, smoking, BMI, dose interval, treatment duration, and corticosteroid use.
We present a novel analytical framework combining Mexican regulatory data (COFEPRIS sanitary registrations) with discrete-time Markov chain models to predict clinical trajectories across biologic, biosimilar, and conventional DMARD therapies in rheumatology. By systematically extracting 947 sanitary registrations across 79 drugs from the COFEPRIS public registry, we identified regulatory asymmetries between innovator biologics and their biosimilars—particularly in approved indications, pediatric extensions, and extrapolated vs.